Prognostic and Immunological Potential of Ribonucleotide Reductase Subunits in Liver Cancer

Figure 2

Correlation analysis of clinicopathological characteristics and expressions of RR subunits in liver cancer tissues. (a) Expressions of RRM1, RRM2, and RRM2B in different age groups (number of years: 177 and number of years: 196). (b) Expressions of RRM1, RRM2, and RRM2B in different ethnic groups (number of Asian:160, number of Black or African American: 17, and number of White: 185). (c) Expressions of RRM1, RRM2, and RRM2B in different gender groups (number of female: 121 and number of male: 253). (d) Expressions of RRM1, RRM2, and RRM2B in different T stage groups (number of T1: 183, number of T2: 95, number of T3: 80, and number of T4: 13). (e) Expressions of RRM1, RRM2, and RRM2B in different grade groups (number of G1: 55, number of G2: 178, and number of G3 and G4: 136). (f) Expressions of RRM1, RRM2, and RRM2B in different stage groups (number of stage I: 173, number of stage II: 87, and number of stages III and IV: 90). (g) Expressions of RRM1, RRM2, and RRM2B in different tumor status groups (number of tumor-free: 202 and number of with tumor: 153). (h) Expressions of RRM1, RRM2, and RRM2B in different alpha-fetoprotein (AFP) protein level groups (number of : 215 and number of : 65). , , and . The “ns” stands for “not significant.” “Tumor-free” means that liver cancer does not continue to be present, indicating no progression of the original liver cancer. “With tumor” means the progression of the original disease.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)